Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70


The effects of comorbidity on colorectal cancer mortality in an Australian cancer population.

Pule ML, Buckley E, Niyonsenga T, Roder D.

Sci Rep. 2019 Jun 12;9(1):8580. doi: 10.1038/s41598-019-44969-8.


Anti-CD1a CAR T cells to selectively target T-ALL.

Maciocia PM, Pule MA.

Blood. 2019 May 23;133(21):2246-2247. doi: 10.1182/blood-2019-03-900910. No abstract available.


Ribosome clearance during RNA interference.

Pule MN, Glover ML, Fire AZ, Arribere JA.

RNA. 2019 May 20. pii: rna.070813.119. doi: 10.1261/rna.070813.119. [Epub ahead of print]


Quantitative in vivo dual-color bioluminescence imaging in the mouse brain.

Aswendt M, Vogel S, Schäfer C, Jathoul A, Pule M, Hoehn M.

Neurophotonics. 2019 Apr;6(2):025006. doi: 10.1117/1.NPh.6.2.025006. Epub 2019 May 7.


Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination.

Kyte JA, Fåne A, Pule M, Gaudernack G.

Oncoimmunology. 2019 Jan 19;8(4):e1565236. doi: 10.1080/2162402X.2019.1565236. eCollection 2019.


Lentiviral Vector Purification Using Genetically Encoded Biotin Mimic in Packaging Cell.

Mekkaoui L, Parekh F, Kotsopoulou E, Darling D, Dickson G, Cheung GW, Chan L, MacLellan-Gibson K, Mattiuzzo G, Farzaneh F, Takeuchi Y, Pule M.

Mol Ther Methods Clin Dev. 2018 Oct 23;11:155-165. doi: 10.1016/j.omtm.2018.10.008. eCollection 2018 Dec 14.


CAR T-cell Integration of Multiple Input Signals Allows for Precise Targeting of Cancer.

Achkova D, Pule M.

Cancer Discov. 2018 Aug;8(8):918-920. doi: 10.1158/2159-8290.CD-18-0672.


A Rapamycin-Activated Caspase 9-Based Suicide Gene.

Stavrou M, Philip B, Traynor-White C, Davis CG, Onuoha S, Cordoba S, Thomas S, Pule M.

Mol Ther. 2018 May 2;26(5):1266-1276. doi: 10.1016/j.ymthe.2018.03.001. Epub 2018 Mar 9.


Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.

Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA.

Cancer Cell. 2018 Apr 9;33(4):649-663.e4. doi: 10.1016/j.ccell.2018.02.010. Epub 2018 Mar 22.


An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.

Lee L, Draper B, Chaplin N, Philip B, Chin M, Galas-Filipowicz D, Onuoha S, Thomas S, Baldan V, Bughda R, Maciocia P, Kokalaki E, Neves MP, Patel D, Rodriguez-Justo M, Francis J, Yong K, Pule M.

Blood. 2018 Feb 15;131(7):746-758. doi: 10.1182/blood-2017-05-781351. Epub 2017 Dec 28.


Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.

Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, Legut M, Cole DK, Sewell AK, Gritti G, Somja J, Piris MA, Peggs KS, Linch DC, Marafioti T, Pule MA.

Nat Med. 2017 Dec;23(12):1416-1423. doi: 10.1038/nm.4444. Epub 2017 Nov 13.


Evolving adoptive cellular therapies in urological malignancies.

Wong YNS, Joshi K, Pule M, Peggs KS, Swanton C, Quezada SA, Linch M.

Lancet Oncol. 2017 Jun;18(6):e341-e353. doi: 10.1016/S1470-2045(17)30327-3. Review.


Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA.

Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.013. Epub 2017 Apr 11.


Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.

Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, Clifton-Hadley L, Champion K, Sattar Z, Popova B, Hackshaw A, Smith P, Roberts T, Biagi E, Dreno B, Rousseau R, Kailayangiri S, Ahlmann M, Hough R, Kremens B, Sauer MG, Veys P, Goulden N, Cummins M, Amrolia PJ.

Leukemia. 2017 May;31(5):1087-1095. doi: 10.1038/leu.2017.39. Epub 2017 Jan 27.


T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy.

Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M.

Oncoimmunology. 2016 Oct 24;5(12):e1249090. doi: 10.1080/2162402X.2016.1249090. eCollection 2016.


Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.

Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S, Pinner D, Ahsan G, Gilmour K, Lucchini G, Inglott S, Mifsud W, Chiesa R, Peggs KS, Chan L, Farzeneh F, Thrasher AJ, Vora A, Pule M, Veys P.

Sci Transl Med. 2017 Jan 25;9(374). pii: eaaj2013. doi: 10.1126/scitranslmed.aaj2013. Erratum in: Sci Transl Med. 2017 Feb 15;9(377):null.


Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.

Mock U, Nickolay L, Philip B, Cheung GW, Zhan H, Johnston IC, Kaiser AD, Peggs K, Pule M, Thrasher AJ, Qasim W.

Cytotherapy. 2016 Aug;18(8):1002-11. doi: 10.1016/j.jcyt.2016.05.009.


TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.

Menger L, Sledzinska A, Bergerhoff K, Vargas FA, Smith J, Poirot L, Pule M, Hererro J, Peggs KS, Quezada SA.

Cancer Res. 2016 Apr 15;76(8):2087-93. doi: 10.1158/0008-5472.CAN-15-3352. Erratum in: Cancer Res. 2017 Jun 15;77(12 ):3379. Cancer Res. 2016 Oct 15;76(20):6130.


An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers.

Thomas S, Straathof K, Himoudi N, Anderson J, Pule M.

PLoS One. 2016 Mar 31;11(3):e0152196. doi: 10.1371/journal.pone.0152196. eCollection 2016.


Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy.

Maciocia P, Badat M, Cheesman S, D'Sa S, Joshi R, Lambert J, Mohamedbhai S, Pule M, Linch D, Ardeshna K.

Br J Haematol. 2016 Feb;172(4):545-53. doi: 10.1111/bjh.13867. Epub 2015 Dec 18.


Flow-Based Single Cell Deposition for High-Throughput Screening of Protein Libraries.

Stowe C, Pizzey A, Kalber T, Badar A, Lythgoe M, Pule M.

PLoS One. 2015 Nov 4;10(11):e0140730. doi: 10.1371/journal.pone.0140730. eCollection 2015.


TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells.

Menger L, Gouble A, Marzolini MA, Pachnio A, Bergerhoff K, Henry JY, Smith J, Pule M, Moss P, Riddell SR, Quezada SA, Peggs KS.

Blood. 2015 Dec 24;126(26):2781-9. doi: 10.1182/blood-2015-08-664755. Epub 2015 Oct 27.


Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.

Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, Potrel P, Bas C, Lemaire L, Galetto R, Lebuhotel C, Eyquem J, Cheung GW, Duclert A, Gouble A, Arnould S, Peggs K, Pule M, Scharenberg AM, Smith J.

Cancer Res. 2015 Sep 15;75(18):3853-64. doi: 10.1158/0008-5472.CAN-14-3321. Epub 2015 Jul 16.


Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma.

Gohil SH, Ardeshna KM, Lambert JM, Pule MA, Mohamedbhai S, Virchis A, Morris EC, Linch DC, Thomson KJ, Peggs KS.

Br J Haematol. 2015 Oct;171(2):197-204. doi: 10.1111/bjh.13561. Epub 2015 Jun 26.


Genetic Regulation of Fate Decisions in Therapeutic T Cells to Enhance Tumor Protection and Memory Formation.

Veliça P, Zech M, Henson S, Holler A, Manzo T, Pike R, Santos E Sousa P, Zhang L, Heinz N, Schiedlmeier B, Pule M, Stauss H, Chakraverty R.

Cancer Res. 2015 Jul 1;75(13):2641-52. doi: 10.1158/0008-5472.CAN-14-3283. Epub 2015 Apr 22. Erratum in: Cancer Res. 2015 Dec 15;75(24):5402. Heinz, Niels [added].


Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.

Gilham DE, Anderson J, Bridgeman JS, Hawkins RE, Exley MA, Stauss H, Maher J, Pule M, Sewell AK, Bendle G, Lee S, Qasim W, Thrasher A, Morris E.

Hum Gene Ther. 2015 May;26(5):276-85. doi: 10.1089/hum.2015.024. Review.


Fluorescence-guided development of a tricistronic vector encoding bimodal optical and nuclear genetic reporters for in vivo cellular imaging.

Badar A, Kiru L, Kalber TL, Jathoul A, Straathof K, Årstad E, Lythgoe MF, Pule M.

EJNMMI Res. 2015 Mar 28;5:18. doi: 10.1186/s13550-015-0097-z. eCollection 2015.


CD19 chimeric antigen receptor T cell therapy for haematological malignancies.

Ghorashian S, Pule M, Amrolia P.

Br J Haematol. 2015 May;169(4):463-78. doi: 10.1111/bjh.13340. Epub 2015 Mar 5. Review.


Chimeric antigen receptor T cells for ALL.

Amrolia PJ, Pule M.

Lancet. 2015 Feb 7;385(9967):488-90. doi: 10.1016/S0140-6736(14)61729-3. Epub 2014 Oct 13. No abstract available.


A dual-color far-red to near-infrared firefly luciferin analogue designed for multiparametric bioluminescence imaging.

Jathoul AP, Grounds H, Anderson JC, Pule MA.

Angew Chem Int Ed Engl. 2014 Nov 24;53(48):13059-63. doi: 10.1002/anie.201405955. Epub 2014 Sep 29. Erratum in: Angew Chem Int Ed Engl. 2015 Feb 2;54(6):1698.


Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.

Ricciardelli I, Blundell MP, Brewin J, Thrasher A, Pule M, Amrolia PJ.

Blood. 2014 Oct 16;124(16):2514-22. doi: 10.1182/blood-2014-01-553362. Epub 2014 Sep 2.


A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.

Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, Marin V, Marafioti T, Chakraverty R, Linch D, Quezada SA, Peggs KS, Pule M.

Blood. 2014 Aug 21;124(8):1277-87. doi: 10.1182/blood-2014-01-545020. Epub 2014 Jun 26.


In vitro characterization of genetically expressed absorbing proteins using photoacoustic spectroscopy.

Laufer J, Jathoul A, Pule M, Beard P.

Biomed Opt Express. 2013 Oct 14;4(11):2477-90. doi: 10.1364/BOE.4.002477. eCollection 2013.


Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy.

Ricciardelli I, Brewin J, Lugthart G, Albon SJ, Pule M, Amrolia PJ.

Am J Transplant. 2013 Dec;13(12):3244-52. doi: 10.1111/ajt.12475. Epub 2013 Oct 8.


Artemisinin therapy and severe delayed haemolysis.

Jarvis JN, Coltart CE, Pule M, Chiodini PL, Doherty T.

Lancet. 2013 Jul 13;382(9887):180. doi: 10.1016/S0140-6736(13)60812-0. No abstract available.


Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.

Marin V, Cribioli E, Philip B, Tettamanti S, Pizzitola I, Biondi A, Biagi E, Pule M.

Hum Gene Ther Methods. 2012 Dec;23(6):376-86. doi: 10.1089/hgtb.2012.050.


CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

Gilham DE, Debets R, Pule M, Hawkins RE, Abken H.

Trends Mol Med. 2012 Jul;18(7):377-84. doi: 10.1016/j.molmed.2012.04.009. Epub 2012 May 19. Review.


Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK.

Blood. 2011 Dec 1;118(23):6050-6. doi: 10.1182/blood-2011-05-354449. Epub 2011 Oct 7.


In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy.

Pizzitola I, Agostoni V, Cribioli E, Pule M, Rousseau R, Finney H, Lawson A, Biondi A, Biagi E, Marin V.

J Immunother. 2011 Jul-Aug;34(6):469-79. doi: 10.1097/CJI.0b013e31821e763b.


Transiently redirected T cells for adoptive transfer.

Almåsbak H, Rian E, Hoel HJ, Pulè M, Wälchli S, Kvalheim G, Gaudernack G, Rasmussen AM.

Cytotherapy. 2011 May;13(5):629-40. doi: 10.3109/14653249.2010.542461. Epub 2010 Dec 21.


Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.

Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE.

J Immunother. 2010 Oct;33(8):780-8. doi: 10.1097/CJI.0b013e3181ee6675.


Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.

Marin V, Pizzitola I, Agostoni V, Attianese GM, Finney H, Lawson A, Pule M, Rousseau R, Biondi A, Biagi E.

Haematologica. 2010 Dec;95(12):2144-52. doi: 10.3324/haematol.2010.026310. Epub 2010 Aug 16.


Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo.

Landmeier S, Altvater B, Pscherer S, Meltzer J, Sebire N, Pule M, Vera J, Hotfilder M, Juergens H, Vormoor J, Rossig C.

Leukemia. 2010 May;24(5):1080-4. doi: 10.1038/leu.2010.38. Epub 2010 Mar 11. No abstract available.


Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy.

Samarasinghe S, Mancao C, Pule M, Nawroly N, Karlsson H, Brewin J, Openshaw P, Gaspar HB, Veys P, Amrolia PJ.

Blood. 2010 Jan 14;115(2):396-407. doi: 10.1182/blood-2009-08-235895. Epub 2009 Nov 4.


Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM.

Blood. 2010 Feb 4;115(5):925-35. doi: 10.1182/blood-2009-08-239186. Epub 2009 Oct 30.


Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease.

Brewin J, Mancao C, Straathof K, Karlsson H, Samarasinghe S, Amrolia PJ, Pule M.

Blood. 2009 Nov 26;114(23):4792-803. doi: 10.1182/blood-2009-07-228387. Epub 2009 Sep 21.


Red-emitting luciferases for bioluminescence reporter and imaging applications.

Branchini BR, Ablamsky DM, Davis AL, Southworth TL, Butler B, Fan F, Jathoul AP, Pule MA.

Anal Biochem. 2010 Jan 15;396(2):290-7. doi: 10.1016/j.ab.2009.09.009. Epub 2009 Sep 11.


2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.

Altvater B, Landmeier S, Pscherer S, Temme J, Schweer K, Kailayangiri S, Campana D, Juergens H, Pule M, Rossig C.

Clin Cancer Res. 2009 Aug 1;15(15):4857-66. doi: 10.1158/1078-0432.CCR-08-2810. Epub 2009 Jul 28.


Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S.

Mol Ther. 2009 Oct;17(10):1779-87. doi: 10.1038/mt.2009.133. Epub 2009 Jun 16.


2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells.

Altvater B, Landmeier S, Pscherer S, Temme J, Juergens H, Pule M, Rossig C.

Cancer Immunol Immunother. 2009 Dec;58(12):1991-2001. doi: 10.1007/s00262-009-0704-9. Epub 2009 Apr 10.


Supplemental Content

Support Center